19 results on '"Yue Zhong"'
Search Results
2. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia
- Author
-
James S. Blachly, Anna Reister Schultz, Maximilian Schmutz, Christopher C. Oakes, Brian J. Druker, Bethany L. Mundy-Bosse, Min Wang, Sebastian Vosberg, Ramiro Garzon, Lars Bullinger, Philipp A. Greif, Ann-Kathrin Eisfeld, Rainer Claus, John C. Byrd, Clara D. Bloomfield, Yue Zhong Wu, Kevin R. Coombes, Brian Giacopelli, Ada C Cleary, and Jeffrey W. Tyner
- Subjects
Cancer Research ,Myeloid ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Gene expression ,Genetics ,medicine ,Humans ,ddc:610 ,Promoter Regions, Genetic ,Enhancer ,Transcription factor ,Genetics (clinical) ,030304 developmental biology ,0303 health sciences ,Research ,Myeloid leukemia ,Methylation ,DNA Methylation ,Phenotype ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Mutation ,DNA methylation ,030217 neurology & neurosurgery - Abstract
Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles and involving numerous pathogenic mechanisms and pathways. Integration of molecular data types across multiple patient cohorts may advance current genetic approaches for improved subclassification and understanding of the biology of the disease. Here, we analyzed genome-wide DNA methylation in 649 AML patients using Illumina arrays and identified a configuration of 13 subtypes (termed “epitypes”) using unbiased clustering. Integration of genetic data revealed that most epitypes were associated with a certain recurrent mutation (or combination) in a majority of patients, yet other epitypes were largely independent. Epitypes showed developmental blockage at discrete stages of myeloid differentiation, revealing epitypes that retain arrested hematopoietic stem-cell-like phenotypes. Detailed analyses of DNA methylation patterns identified unique patterns of aberrant hyper- and hypomethylation among epitypes, with variable involvement of transcription factors influencing promoter, enhancer, and repressed regions. Patients in epitypes with stem-cell-like methylation features showed inferior overall survival along with up-regulated stem cell gene expression signatures. We further identified a DNA methylation signature involving STAT motifs associated with FLT3-ITD mutations. Finally, DNA methylation signatures were stable at relapse for the large majority of patients, and rare epitype switching accompanied loss of the dominant epitype mutations and reversion to stem-cell-like methylation patterns. These results show that DNA methylation-based classification integrates important molecular features of AML to reveal the diverse pathogenic and biological aspects of the disease.
- Published
- 2021
3. DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia
- Author
-
Yue-Zhong Wu, Ann-Kathrin Eisfeld, Clara D. Bloomfield, Brian Giacopelli, Min Wang, Kevin R. Coombes, John C. Byrd, Brian J. Druker, Anna Reister Schultz, James S. Blachly, Jeffrey W. Tyner, Ada C Cleary, and Christopher C. Oakes
- Subjects
Immunology ,JAK-STAT signaling pathway ,Myeloid leukemia ,Cancer ,Cell Biology ,Hematology ,Methylation ,Biology ,medicine.disease ,Biochemistry ,Chromatin ,chemistry.chemical_compound ,chemistry ,DNA methylation ,Cancer research ,medicine ,Transcription factor ,health care economics and organizations ,DNA - Abstract
Background Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor survival. Recurrent genetic aberrations, such as chromosomal rearrangements and gene mutations, are currently used for patient classification and prognosis, and form the basis of our current understanding of pathogenic mechanisms. However, these markers incompletely predict disease behavior and outcomes. Alterations in DNA methylation patterns are a major hallmark of cancer and recent studies have demonstrated differential global DNA methylation patterns among AML patients. Here we sought to define a novel approach to classify AML patients using genome-wide DNA methylation patterns and to uncover the biological basis and features associated with these epigenetic patterns by integrating mutation, gene expression, and functional data. Methods We analyzed genome-wide DNA methylation data from Illumina arrays on 649 AML cases combined from the Beat AML consortium housed at the Oregon Health & Science University (OHSU) (n=226), The Ohio State University (n=27), TCGA (n=190), and other published studies (n=206). Small molecule inhibitor response data was obtained from the Beat AML consortium. RNA sequencing and survival analyses were performed by Kaplan-Meier analysis in the TCGA and OHSU cohorts. Results K-mediods based clustering on the 500 most-variable CpGs identified 13 distinct subtypes, we termed AML 'epitypes' (Fig. 1A). Comparative analyses incorporating normal hematopoietic cells revealed that AML epitypes retain unique combinations of biological features including the degree of myeloid development, chromatin landscapes, transcription factor binding and gene expression patterns/pathways. Eleven of 13 epitypes were associated with somatic genetic aberrations, i.e. mutations (or combinations thereof) in NPM1, IDH1/2, TET2, DNMT3A, CEBPA, and chromosomal rearrangements t(8;21), t(15;17) and inv(16) accounted for the majority of patients within each respective epitype. The remaining two epitypes were not associated with dominant genetic events, rather they clustered closely with normal CD34+ hematopoietic stem and progenitor cells. These 'stem-like' epigenetic patterns accounted for 27% of patients and showed limited correlation to other leukemic stem cell gene expression signatures. Stem-like epitypes demonstrated broad resistance to a range of small molecule inhibitors. Differential gene expression analysis between normal cells and epitypes revealed enrichment of the JAK-STAT pathway along with other inflammatory pathways, such as interleukin and interferon signaling, selectively in the stem-like epitypes. Patients with stem-like epitypes exhibited decreased overall survival relative to others independent of age (P We next investigated the impact of STAT pathway activation on AML epigenetic patterns. FLT3 mutations are known to selectively activate the STAT pathway in AML and are associated with inferior outcomes. Controlling for the distribution of FLT3 mutations across epitypes, we uncovered a hypomethylation signature enriched in STAT transcription factor binding and FLT3 mutations which we have termed the 'STAT hypomethylation signature' (SHS). SHS-positivity was not restricted to FLT3 mutations, as 34% of SHS+ AMLs lacked FLT3 mutations and, conversely, SHS was absent in 24% of FLT3 mutated patients. SHS-positivity did not impact outcome in the stem-like epitypes; however, within non-stem-like epitypes, SHS+ patients displayed significantly poorer outcomes (P=0.021; Fig 1C). Conclusion Applying our integrative approach of using global DNA methylation profiles to subclassify AML patients, we have uncovered new insights into potential pathogenic mechanisms by which genetic and epigenetic aberrations may contribute to discrete avenues of AML development. Distinct global DNA methylation patterns are commonly driven by genetic aberrations, while others were associated with stem cell-like features and inflammatory pathways. The identification of JAK/STAT pathway upregulation in the stem-like epitype and a subset of non-stem-like samples highlights that nearly half of AML patients exhibit evidence of JAK/STAT activation and experience poor outcomes. Disclosures Druker: Dana-Farber Cancer Institute (antibody royalty): Patents & Royalties: #2524, antibody royalty; Bristol-Myers Squibb: Patents & Royalties, Research Funding; Pfizer: Other: PI or co-investigator on clinical trial(s) funded via contract with OHSU., Research Funding; Bristol-Myers Squibb: Other: PI or co-investigator on clinical trial(s) funded via contract with OHSU., Research Funding; Merck & Co: Patents & Royalties: Dana-Farber Cancer Institute license #2063, Monoclonal antiphosphotyrosine antibody 4G10, exclusive commercial license to Merck & Co; Celgene: Consultancy; Vivid Biosciences: Membership on an entity's Board of Directors or advisory committees, Other: Stock options; The RUNX1 Research Program: Membership on an entity's Board of Directors or advisory committees; Patient True Talk: Consultancy; GRAIL: Equity Ownership, Other: former member of Scientific Advisory Board; Beat AML LLC: Other: Service on joint steering committee; Cepheid: Consultancy, Honoraria; Burroughs Wellcome Fund: Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Beta Cat: Membership on an entity's Board of Directors or advisory committees, Other: Stock options; Aptose Biosciences: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Amgen: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; ALLCRON: Membership on an entity's Board of Directors or advisory committees; ICON: Other: Scientific Founder of Molecular MD, which was acquired by ICON in Feb. 2019; Gilead Sciences: Other: former member of Scientific Advisory Board; CureOne: Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Aileron Therapeutics: #2573, Constructs and cell lines harboring various mutations in TNK2 and PTPN11, licensing fees , Membership on an entity's Board of Directors or advisory committees; Monojul: Other: former consultant; Novartis: Other: PI or co-investigator on clinical trial(s) funded via contract with OHSU., Patents & Royalties: Patent 6958335, Treatment of Gastrointestinal Stromal Tumors, exclusively licensed to Novartis, Research Funding; OHSU (licensing fees): Patents & Royalties: #2573, Constructs and cell lines harboring various mutations in TNK2 and PTPN11, licensing fees . Tyner:Petra: Research Funding; Janssen: Research Funding; Aptose: Research Funding; Constellation: Research Funding; Genentech: Research Funding; Takeda: Research Funding; Syros: Research Funding; Array: Research Funding; AstraZeneca: Research Funding; Array: Research Funding; Incyte: Research Funding; Gilead: Research Funding; Janssen: Research Funding; Takeda: Research Funding; Seattle Genetics: Research Funding; AstraZeneca: Research Funding; Syros: Research Funding; Seattle Genetics: Research Funding; Constellation: Research Funding; Aptose: Research Funding; Incyte: Research Funding; Agios: Research Funding; Petra: Research Funding; Gilead: Research Funding; Genentech: Research Funding; Agios: Research Funding. Byrd:Acerta: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; Genentech: Research Funding; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel Expenses, Speakers Bureau; Ohio State University: Patents & Royalties: OSU-2S; Ohio State University: Patents & Royalties: OSU-2S; BeiGene: Research Funding; Acerta: Research Funding; BeiGene: Research Funding; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau; Acerta: Research Funding; Ohio State University: Patents & Royalties: OSU-2S; BeiGene: Research Funding; Genentech: Research Funding; Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau.
- Published
- 2019
4. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
- Author
-
Stephen Lee, Michael A. Caligiuri, Laura Z. Rassenti, Zunyan Dai, Li Yu, Chunhui Liu, Te Hui Liu, Christoph Plass, Charlene Mao, Aparna Raval, Jeff Vandeusen, John C. Byrd, Wei Ding, Laura T. Smith, Guido Marcucci, Shujun Liu, Yue Zhong Wu, and Brian Becknell
- Subjects
Tumor suppressor gene ,Molecular Sequence Data ,Restriction landmark genomic scanning ,Biology ,Malignant transformation ,Mice ,Genetics ,medicine ,Animals ,Humans ,Genes, Tumor Suppressor ,Gene Silencing ,Epigenetics ,Promoter Regions, Genetic ,Leukemia ,Cancer ,Neoplasms, Experimental ,Methylation ,DNA Methylation ,medicine.disease ,DNA-Binding Proteins ,Disease Models, Animal ,DNA methylation ,Inhibitor of Differentiation Proteins ,Transcription Factors - Abstract
DNA methylation is associated with malignant transformation, but limitations imposed by genetic variability, tumor heterogeneity, availability of paired normal tissues and methodologies for global assessment of DNA methylation have limited progress in understanding the extent of epigenetic events in the initiation and progression of human cancer and in identifying genes that undergo methylation during cancer. We developed a mouse model of T/natural killer acute lymphoblastic leukemia that is always preceded by polyclonal lymphocyte expansion to determine how aberrant promoter DNA methylation and consequent gene silencing might be contributing to leukemic transformation. We used restriction landmark genomic scanning with this mouse model of preleukemia reproducibly progressing to leukemia to show that specific genomic methylation is associated with only the leukemic phase and is not random. We also identified Idb4 as a putative tumor-suppressor gene that is methylated in most mouse and human leukemias but in only a minority of other human cancers.
- Published
- 2005
5. Aberrant Methylation and Decreased Expression of NRIP1 in IGHV-Unmutated CLL
- Author
-
Yue-Zhong Wu, Madelyn M. Gerber, Christopher C. Oakes, Yali Zhu, Kevin R. Coombes, Brian Giacopelli, and Lynne V. Abruzzo
- Subjects
Immunology ,Cell Biology ,Hematology ,Methylation ,Biology ,Biochemistry ,Molecular biology ,Epigenetics of physical exercise ,Differentially methylated regions ,CpG site ,immune system diseases ,hemic and lymphatic diseases ,Gene expression ,DNA methylation ,IGHV@ ,Gene - Abstract
Aberrant DNA methylation patterning occurs in many cancers, including chronic lymphocytic leukemia (CLL). Methylation programming changes as B cells differentiate from immature progenitors to mature B cells. CLL clones originate from a continuum of B cell maturation states, which differ in their "methylome." Emerging evidence suggests that aberrant methylation programming occurs at numerous genes that are differentially expressed in IGHV-defined CLL subtypes. Nuclear receptor interacting protein 1 (NRIP1) reproducibly shows significant gene expression differences in IGHV unmutated (U-CLL) and mutated CLL (M-CLL), with lower transcript levels observed in U-CLL cells. Low expression of NRIP1 is associated with poorer overall survival and time-to-treatment. NRIP1 encodes a cofactor that interacts with various nuclear receptors and other proteins to regulate transcription of genes involved in cellular proliferation, survival, metabolism, inflammation, and other processes. Published data reveal several CpG dinucleotides near the NRIP1 promoter that undergo increasing methylation during the maturation and differentiation of normal peripheral blood B cells (NBC), concordant with a stepwise decrease in transcript levels of NRIP1 over the course of maturation. Interestingly, our analysis of publically available expression data revealed significantly lower NRIP1 expression in U-CLL cells (the less mature CLL subtype) than NBC, while M-CLL cells (the more mature CLL subtype) express levels comparable to NBC. Given these observations, our objective was to interrogate the promoter and regulatory regions at the NRIP1 locus for differences in CpG methylation in genomic DNA isolated from U-CLL, M-CLL, and NBC. We hypothesized that the NRIP1 locus is more highly methylated in U-CLL than in M-CLL and NBC, and that this increased methylation represses NRIP1 gene transcription, contributing to its aberrantly low expression in U-CLL compared to M-CLL and NBC. We bisulfite-converted genomic DNA from negatively-selected CD19+ treatment-naïve CLL samples (n=74 U-CLL, n=37 M-CLL) and NBC from healthy donors (n=5). We PCR-amplified regions in or near the CpG island of NRIP1 and used Agena Bioscience's EpiTyper kit to prepare the samples for analysis on a MassARRAY spectrometer. EpiTyper software was used to detect mass differences that indicate either non-methylated or methylated CpG-containing fragments, and to calculate their relative frequency in each sample. For each CpG locus that was assayed, we fit a beta-regression model to detect differential methylation between M-CLL and U-CLL. We also computed Pearson correlation coefficients comparing methylation levels to gene expression levels. We assessed 47 CpGs mapping to the promoter and nearby regulatory elements of NRIP1 for methylation frequency and correlation with NRIP1 expression. From our comparison of methylation frequency in U-CLL and M-CLL, 3 adjacent CpG loci were significant at false discovery rate (FDR) =1% (CpG 58, p=0.00016; CpG 144, p=0.00062; and CpG 155, p=0.00287). The three most significant correlation coefficients arose from the same three CpG loci (CpG 58, R=0.677, p=2.2e-16; CpG 144, R=0.539, p=7.16e-10; CpG 155, R=0.651, p=5.77e-15). Unexpectedly, all 3 loci were methylated at higher levels in M-CLL and at lower levels in U-CLL (on average), and expression was positively correlated with methylation levels. These CpGs map near a documented binding site for the repressive transcription factor RUNX3, prompting us to hypothesize that differential methylation in U-CLL versus M-CLL may affect the binding affinity of RUNX3 and contribute to the robust NRIP1 expression differences in these CLL subtypes. Future work will test this hypothesis using gel-shift and luciferase reporter assays followed by chromatin immunoprecipitation experiments. Few studies have focused on aberrant methylation patterning in CLL and the consequences of deregulated gene expression. We are the first to look at NRIP1 for differences in DNA methylation across IGHV subtypes. Future studies aimed at understanding how methylation at this locus affects NRIP1 transcription, as well as how levels of NRIP1 affect cell survival pathways, will enhance our understanding of the role of this gene in CLL, and the contributions of deregulated methylation to disease pathophysiology. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
6. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
- Author
-
Rebecca B. Klisovic, Hok Hei Tam, John Curfman, Michael R. Grever, Klaus H. Metzeler, Pearlly S. Yan, Susan P. Whitman, Ramiro Garzon, Alison Walker, Susan Geyer, Guido Marcucci, William Blum, Mark W. Murphy, Yue Zhong Wu, John C. Byrd, Benjamin Rodriguez, Michael P. Trimarchi, Michael A. Caligiuri, Ralf Bundschuh, Clara D. Bloomfield, Samson T. Jacob, and David Frankhouser
- Subjects
Male ,Antimetabolites, Antineoplastic ,Myeloid ,Immunology ,Azacitidine ,Decitabine ,Biology ,Biochemistry ,Polymerase Chain Reaction ,Cell Line, Tumor ,medicine ,Biomarkers, Tumor ,Humans ,Promoter Regions, Genetic ,Aged ,Oligonucleotide Array Sequence Analysis ,Aged, 80 and over ,Genome, Human ,Gene Expression Profiling ,Myeloid leukemia ,Cell Biology ,Hematology ,Methylation ,DNA, Neoplasm ,DNA Methylation ,medicine.disease ,Molecular biology ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,CpG site ,DNA methylation ,Cancer research ,Female ,medicine.drug - Abstract
The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m2 per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellent toxicity profile. To assess the genome-wide activity of decitabine, we profiled pretreatment and post treatment (day 25/course 1) methylomes of marrow samples from patients (n = 16) participating in the trial using deep-sequencing analysis of methylated DNA captured by methyl-binding protein (MBD2). Decitabine significantly reduced global methylation compared with pretreatment baseline (P = .001). Percent marrow blasts did not correlate with global methylation levels, suggesting that hypomethylation was related to the activity of decitabine rather than to a mere decrease in leukemia burden. Hypomethylation occurred predominantly in CpG islands and CpG island-associated regions (P ranged from .03 to .04) A significant concentration (P < .001) of the hypomehtylated CpG islands was found in chromosome subtelomeric regions, suggesting a differential activity of decitabine in distinct chromosome regions. Hypermethylation occurred much less frequently than hypomethylation and was associated with low CpG content regions. Decitabine-related methylation changes were concordant with those previously reported in distinct genes. In summary, our study supports the feasibility of methylome analyses as a pharmacodynamic endpoint for hypomethylating therapies.
- Published
- 2012
7. DNA- methylation changes in a human cell model of breast cancer progression
- Author
-
Christoph Plass, Yue Zhong Wu, Kara E. Snider, Irma H. Russo, Jose Russo, and Sandra V. Fernandez
- Subjects
Health, Toxicology and Mutagenesis ,Neuregulin-1 ,Restriction landmark genomic scanning ,Bisulfite sequencing ,Breast Neoplasms ,Tumor initiation ,Biology ,medicine.disease_cause ,Polymerase Chain Reaction ,Article ,Epigenesis, Genetic ,chemistry.chemical_compound ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,Epigenetics ,Molecular Biology ,Methylation ,DNA Methylation ,Molecular biology ,Demethylating agent ,chemistry ,DNA methylation ,Disease Progression ,Female ,Carcinogenesis - Abstract
Epigenetic inactivation of genes by DNA hypermethylation plays an important role in carcinogenesis. An in vitro model of human breast epithelial cell transformation was used to study epigenetic changes induced by estradiol during the neoplastic process. Different stages of tumor initiation and progression are represented in this model being MCF-10F the normal stage; trMCF cells, the transformed stage; bsMCF cells, the invasive stage and, caMCF cells, the tumor stage. Global methylation studies by restriction landmark genomic scanning (RLGS) showed an increased DNA methylation during the in the invasive and tumor stages. Expression studies showed that NRG1 (neuregulin 1), CSS3 (chondroitin sulfate synthase 3) and SNIP (SNAP-25-interacting protein) were downregulated in the invasive and tumor cells. The transformed cells showed low expression of STXBP6 (amysin) compared to the parental cells MCF-10F. The treatment of these cells with the demethylating agent 5-aza-dC alone or in combination with the histone deacetylase inhibitor trichostatin increased the expression of NRG1, STXBP6, CSS3 and SNIP confirming that DNA methylation plays an important role in the regulation of the expression of these genes. The NRG1 exon 1 has a region located between −136 and +79 (considering +1, the translational initiation site) rich in CpG sites that was analyzed by methylation specific PCR (MSP). NRG1 exon 1 showed progressive changes in the methylation pattern associated with the progression of the neoplastic process in this model; NRG1 exon 1 was unmethylated in MCF-10F and trMCF cells, becoming hypermethylated in the invasive (bsMCF) and tumor (caMCF) stages. Studies of human breast tissue samples showed that NRG1 exon 1 was partially methylated in 14 out of 17 (82.4%) invasive carcinomas although it was unmethylated in normal tissues (8 out of 10 normal breast tissue samples). Furthermore, NRG1 exon 1 was partially methylated in 9 out of 14 (64.3%) morphologically normal tissue samples adjacent to invasive carcinomas.
- Published
- 2010
8. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning
- Author
-
Dominic J. Smiraglia, Janet S. Rader, Mark E. Sherman, Kathleen R. Cho, Ritu Nayar, Sophia S. Wang, Yue Zhong Wu, Srimoyee Ghosh, Thomas A. Bonfiglio, and Christoph Plass
- Subjects
Genetics ,Cancer Research ,Genome, Human ,Restriction landmark genomic scanning ,Bisulfite sequencing ,Cancer ,Uterine Cervical Neoplasms ,Methylation ,Biology ,DNA Methylation ,medicine.disease ,medicine.disease_cause ,Oncology ,CpG site ,DNA methylation ,medicine ,Cancer research ,Carcinoma, Squamous Cell ,Illumina Methylation Assay ,Humans ,CpG Islands ,Female ,Carcinogenesis - Abstract
Aberrant methylation of CpG islands in gene promoters often represents an early clonal event in carcinogenesis. Accordingly, defining methylation profiles may be useful for developing marker panels for early detection or predicting the risk of cancer precursors. To identify specific genes frequently methylated in cervical cancer, we conducted methylation profiling of 20 primary human cervical cancers using NotI-based restriction landmark genomic scanning (RLGS). Of 2,172 RLGS fragments analyzed (average, 1,753 CpG islands per patient), 186 RLGS fragments were lost in at least one tumor and 40 were lost in three or more. Methylation was identified in 19 (95%) of 20 tumor samples compared with normal DNA. Bisulfite sequencing was conducted to confirm RLGS results. Of the confirmed markers frequently methylated, we developed Methylight assays for two corresponding genes, nucleolar protein 4 (NOL4), and lipoma HMGIC fusion partner–like protein 4 (LHFPL4), which were methylated in 85% and 55% of cancers, respectively. Using these assays, we further confirmed frequent CpG island methylation in the original cancers and in another independent series of 15 cervical cancers. We also showed methylation at a reduced frequency in a set of carefully reviewed cytology specimens demonstrating cells exfoliated from cancer precursor lesions. In summary, we identified, for the first time, NOL4 and LHFPL4 as novel methylation targets specific for cervical cancer. Inclusion of NOL4 and LHFPL4 in evaluating methylation panels for early detection, risk prediction, and etiologic research on cervical cancer is warranted. [Cancer Res 2008;68(7):2489–97]
- Published
- 2008
9. Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing
- Author
-
Joseph Liu, Dustin Potter, Yue Zhong Wu, Shu Huei Wang, Jiejun Wu, Tim H M Huang, Laura T. Smith, and Christoph Plass
- Subjects
Chromatin Immunoprecipitation ,lcsh:QH426-470 ,lcsh:Biotechnology ,Biology ,Decitabine ,Hydroxamic Acids ,Methylation ,Histones ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Epigenetics of physical exercise ,lcsh:TP248.13-248.65 ,Cell Line, Tumor ,Histone methylation ,Genetics ,Histone code ,Animals ,Cancer epigenetics ,Gene Silencing ,Leukemia L1210 ,RNA-Directed DNA Methylation ,DNA Modification Methylases ,030304 developmental biology ,Epigenomics ,Oligonucleotide Array Sequence Analysis ,0303 health sciences ,Lysine ,Acetylation ,DNA Methylation ,lcsh:Genetics ,Gene Expression Regulation ,Mice, Inbred DBA ,030220 oncology & carcinogenesis ,Histone methyltransferase ,DNA methylation ,Azacitidine ,CpG Islands ,Protein Processing, Post-Translational ,Biotechnology ,Research Article - Abstract
Background Previous studies of individual genes have shown that in a self-enforcing way, dimethylation at histone 3 lysine 9 (dimethyl-H3K9) and DNA methylation cooperate to maintain a repressive mode of inactive genes. Less clear is whether this cooperation is generalized in mammalian genomes, such as mouse genome. Here we use epigenomic tools to simultaneously interrogate chromatin modifications and DNA methylation in a mouse leukemia cell line, L1210. Results Histone modifications on H3K9 and DNA methylation in L1210 were profiled by both global CpG island array and custom mouse promoter array analysis. We used chromatin immunoprecipitation microarray (ChIP-chip) to examine acetyl-H3K9 and dimethyl-H3K9. We found that the relative level of acetyl-H3K9 at different chromatin positions has a wider range of distribution than that of dimethyl-H3K9. We then used differential methylation hybridization (DMH) and the restriction landmark genome scanning (RLGS) to analyze the DNA methylation status of the same targets investigated by ChIP-chip. The results of epigenomic profiling, which have been independently confirmed for individual loci, show an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing. In contrast to the previous notion, dimethyl-H3K9 seems to be less distinct in specifying silencing for the genes tested. Conclusion This study demonstrates in L1210 leukemia cells a diverse relationship between histone modifications and DNA methylation in the maintenance of gene silencing. Acetyl-H3K9 shows an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing as expected. However, dimethyl-H3K9 seems to be less distinct in relation to promoter methylation. Meanwhile, a combination of epigenomic tools is of help in understanding the heterogeneity of epigenetic regulation, which may further our vision accumulated from single-gene studies.
- Published
- 2006
10. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line
- Author
-
David R. Hodge, Christoph Plass, James A. Kelley, Celine Pompeia, Yue Zhong Wu, Victor E. Marquez, and William L. Farrar
- Subjects
Cancer Research ,Restriction landmark genomic scanning ,Cytidine ,Biology ,medicine.disease_cause ,Epigenetics of physical exercise ,Ribonucleases ,Cell Line, Tumor ,medicine ,Humans ,Epigenetics ,Gene Silencing ,RNA-Directed DNA Methylation ,Epigenomics ,Oligonucleotide Array Sequence Analysis ,Genome, Human ,Reverse Transcriptase Polymerase Chain Reaction ,Methylation ,DNA Methylation ,Pyrimidine Nucleosides ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Oncology ,DNA methylation ,Cancer research ,Carcinogenesis ,Multiple Myeloma - Abstract
The epigenetic control of gene transcription in cancer has been the theme of many recent studies and therapeutic approaches. Carcinogenesis is frequently associated with hypermethylation and consequent down-regulation of genes that prevent cancer, e.g., those that control cell proliferation and apoptosis. We used the demethylating drug zebularine to induce changes in DNA methylation, then examined patterns of gene expression using cDNA array analysis and Restriction Landmark Genomic Scanning followed by RNase protection assay and reverse transcription-PCR to confirm the results. Microarray studies revealed that many genes were epigenetically regulated by methylation. We concluded that methylation decreased the expression of, or silenced, several genes, contributing to the growth and survival of multiple myeloma cells. For example, a number of genes (BAD, BAK, BIK, and BAX) involved in apoptosis were found to be suppressed by methylation. Sequenced methylation-regulated DNA fragments identified by Restriction Landmark Genomic Scanning were found to contain CpG islands, and some corresponded to promoters of genes that were regulated by methylation. We also observed that after the removal of the demethylating drug, the addition of interleukin 6 restored CpG methylation and re-established previously silenced gene patterns, thus implicating a novel role of interleukin 6 in processes regulating epigenetic gene repression and carcinogenesis.
- Published
- 2004
11. Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia
- Author
-
Jeff Vandeusen, Brian Becknell, Zunyan Dai, John C. Byrd, Laura T. Smith, Yue-Zhong Wu, Stephen Lee, Li Yu, Charlene Mao, Wei Ding, Michael A. Caligiuri, Chunhui Liu, Guido Marcucci, Aparna Raval, Te-Hui Liu, Shujun Liu, Laura Z. Rassenti, and Christoph Plass
- Subjects
Tumor suppressor gene ,Lymphocyte ,Immunology ,Restriction landmark genomic scanning ,Promoter ,Cell Biology ,Hematology ,Methylation ,Biology ,medicine.disease ,Biochemistry ,Molecular biology ,Leukemia ,medicine.anatomical_structure ,Polyclonal antibodies ,medicine ,biology.protein ,Gene silencing - Abstract
We developed a mouse model of acute T/natural killer (NK) acute lymphoblastic leukemia (ALL) that is always preceded by polyclonal lymphocyte expansion to determine how aberrant promoter DNA methylation and consequent gene silencing might be contributing to leukemic transformation. We demonstrated the non-random nature of methylation in the transformation from benign polyclonal expansion to leukemia, and identified a novel tumor suppressor gene silenced in the majority of human leukemia but not solid tumors. To this, we utilized restriction landmark genomic scanning (RLGS) on eight IL-15 transgenic (tg) mice with T/NK ALL, and performed RLGS on an additional five spleens from IL-15tg mice without ALL, but with polyclonal T/NK expansion, and on four spleens from wild type (wt) mice. A total of 2447 RLGS fragments with good resolution on each RLGS profile were analyzed. Only 1–2 variable changes were detected in either wt or polyclonal T/NK expansion controls. In contrast, the eight spleens with clonal T/NK leukemia had 45 to 209 changes (1.8 to 8.5% of total fragments) consistent with aberrant DNA methylation. The association of RLGS fragment losses or reduced intensity with leukemic transformation versus polyclonal expansion was highly significant (P
- Published
- 2004
12. CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells.
- Author
-
Opavsky, Rene, Shu-Huei Wang, Trikha, Prashant, Raval, Aparna, Yuan Huang, Yue-Zhong Wu, Rodriguez, Benjamin, Keller, Benjamin, Liyanarachchi, Sandya, Guo Wei, Davuluri, Ramana V., Weinstein, Michael, Felsher, Dean, Ostrowski, Michael, Leone, Gustavo, and Plass, Christoph
- Subjects
PROMOTERS (Genetics) ,DNA ,METHYLATION ,TUMORS ,CANCER ,EPIGENESIS ,GENE silencing - Abstract
Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing.
- Author
-
Jiejun Wu, Shu-Huei Wang, Potter, Dustin, Liu, Joseph C, Smith, Laura T, Yue-Zhong Wu, Huang, Tim H-M, and Plass, Christoph
- Subjects
HISTONES ,LYSINE ,METHYLATION ,ETHANES ,CELL lines ,GENE silencing - Abstract
Background: Previous studies of individual genes have shown that in a self-enforcing way, dimethylation at histone 3 lysine 9 (dimethyl-H3K9) and DNA methylation cooperate to maintain a repressive mode of inactive genes. Less clear is whether this cooperation is generalized in mammalian genomes, such as mouse genome. Here we use epigenomic tools to simultaneously interrogate chromatin modifications and DNA methylation in a mouse leukemia cell line, L1210. Results: Histone modifications on H3K9 and DNA methylation in L1210 were profiled by both global CpG island array and custom mouse promoter array analysis. We used chromatin immunoprecipitation microarray (ChIP-chip) to examine acetyl-H3K9 and dimethyl-H3K9. We found that the relative level of acetyl-H3K9 at different chromatin positions has a wider range of distribution than that of dimethyl-H3K9. We then used differential methylation hybridization (DMH) and the restriction landmark genome scanning (RLGS) to analyze the DNA methylation status of the same targets investigated by ChIP-chip. The results of epigenomic profiling, which have been independently confirmed for individual loci, show an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing. In contrast to the previous notion, dimethyl-H3K9 seems to be less distinct in specifying silencing for the genes tested. Conclusion: This study demonstrates in L1210 leukemia cells a diverse relationship between histone modifications and DNA methylation in the maintenance of gene silencing. Acetyl-H3K9 shows an inverse relationship between DNA methylation and histone acetylation in regulating gene silencing as expected. However, dimethyl-H3K9 seems to be less distinct in relation to promoter methylation. Meanwhile, a combination of epigenomic tools is of help in understanding the heterogeneity of epigenetic regulation, which may further our vision accumulated from single-gene studies. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
14. Effects of β-cyclodextrins on the enzymatical hydrolysis of chiral dichlorprop methyl ester.
- Author
-
Wen Yue-zhong, Zhou Shan-shan, Fang Zhao-hua, and Liu Wei-ping
- Subjects
- *
CYCLODEXTRINS , *HYDROLYSIS , *LIPASES , *METHYLATION , *SPECTRUM analysis , *ALKYLATION - Abstract
The effect of β-cyclodextrins (β-CDs) on the enzymatical hydrolysis of chiral dichlorprop methyl ester (DCPPM) was studied.Four kinds of β-cyclodextrins (β-cyclodextrin, Partly methylated-CD (PM-β-CD), hydroxypropyl-cyclodextrin (HP-β-CD) and carboxymethyl-cyclodextrin (CM-β-CD) ) were used. Compared with 100% DCPPM in the absence of β-cyclodextrins, the activity of lipase decreased with the increase of β-cyclodextrin and PM-β-cyclodextrin. However, CM-β-cyclodextrin stimulated the lipase activity. The inhibition effect of β-cyclodextrin and PM-β-cyclodextrin on the hydrolysis of DCPPM is affected by many factors other than degree of the methylation blocking the active site of lipase. UV-Vis and Fourier transform infrared (FTIR) spectroscopy studies of the complexation of aqueous DCPPM with β-CDs provide fresh insight into the molecular structure of the complex and explain the effects of β-CDs on enzymatical hydrolysis of chiral DCPPM. Data showed that inclusion complexes had formed by complexation of the CM-β-CD with DCPPM and the solubility of DCPPM was increased in water, which leaded to the increased lipase activity. [ABSTRACT FROM AUTHOR]
- Published
- 2005
15. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.
- Author
-
Li Yu, Chunhui Liu, Vandeusen, Jeff, Becknell, Brian, Zunyan Dai, Yue-Zhong Wu, Raval, Aparna, Te-Hui Liu, Wei Ding, Charlene Mao, Shujun Liu, Smith, Laura T, Lee, Stephen, Rassenti, Laura, Marcucci, Guido, Byrd, John, Caligiuri, Michael A, and Plass, Christoph
- Subjects
METHYLATION ,LYMPHOCYTIC leukemia ,CANCER ,DNA ,TUMORS ,GENETIC regulation - Abstract
DNA methylation is associated with malignant transformation, but limitations imposed by genetic variability, tumor heterogeneity, availability of paired normal tissues and methodologies for global assessment of DNA methylation have limited progress in understanding the extent of epigenetic events in the initiation and progression of human cancer and in identifying genes that undergo methylation during cancer. We developed a mouse model of T/natural killer acute lymphoblastic leukemia that is always preceded by polyclonal lymphocyte expansion to determine how aberrant promoter DNA methylation and consequent gene silencing might be contributing to leukemic transformation. We used restriction landmark genomic scanning with this mouse model of preleukemia reproducibly progressing to leukemia to show that specific genomic methylation is associated with only the leukemic phase and is not random. We also identified Idb4 as a putative tumor-suppressor gene that is methylated in most mouse and human leukemias but in only a minority of other human cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
16. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
- Author
-
Motiwala, Tasneem, Ghoshal, Kalpana, Das, Anindita, Majumder, Sarmila, Weichenhan, Dieter, Wu, Yue-Zhong, Holman, Kristen, James, S Jill, Jacob, Samson T, and Plass, Christoph
- Subjects
DNA ,METHYLATION ,LIVER cancer ,CANCER ,ONCOGENES - Abstract
A diet lacking folic acid and choline and low in methionine (folate/methyl deficient diet, FMD diet) fed to rats is known to produce preneoplastic nodules (PNNs) after 36 weeks and hepatocellular carcinomas (tumors) after 54 weeks. FMD diet-induced tumors exhibit global hypomethylation and regional hypermethylation. Restriction landmark genome scanning analysis with methylation-sensitive enzyme NotI (RLGS-M) of genomic DNA isolated from control livers, PNNs and tumor tissues was performed to identify the genes that are differentially methylated or amplified during multistage hepatocarcinogenesis. Out of the 1250 genes analysed, 2 to 5 genes were methylated in the PNNs, whereas 5 to 45 genes were partially or completely methylated in the tumors. This analysis also showed amplification of 3 to 12 genes in the primary tumors. As a first step towards identifying the genes methylated in the PNNs and primary hepatomas, we generated a rat NotI-EcoRV genomic library in the pBluescriptKS vector. Here, we describe identification of one methylated and downregulated gene as the rat protein tyrosine phosphatase receptor type O (PTPRO) and one amplified gene as rat C-MYC. Methylation of PTPRO at the NotI site located immediate upstream of the trancription start site in the PNNs and tumors, and amplification of C-MYC gene in the tumors were confirmed by Southern blot analyses. Bisulfite genomic sequencing of the CpG island encompassing exon 1 of the PTPRO gene revealed dense methylation in the PNNs and tumors, whereas it was methylation free in the livers of animals on normal diet. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed significant decrease in the expression of PTPRO in the tumors and in a transplanted rat hepatoma. The expression of PTPRO mRNA in the transplanted hepatoma after demethylation with 5-azacytidine, a potent inhibitor of DNA methyltransferases, further confirmed the role of methylation in PTPRO gene expression. These results demonstrate alteration in methylation profile and expression of specific genes during tumor progression in the livers of rats in response to folate/methyl deficiency, and further implicate the potential role of PTPRO as a novel growth regulatory gene at least in the hepatocellular carcinomas.Oncogene (2003) 22, 6319-6331. doi:10.1038/sj.onc.1206750 [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
17. DNA methylation changes in a human cell model of breast cancer progression
- Author
-
Fernandez, Sandra V., Snider, Kara E., Wu, Yue-Zhong, Russo, Irma H., Plass, Christoph, and Russo, Jose
- Subjects
- *
DNA , *METHYLATION , *BREAST cancer , *ESTRADIOL , *CELL transformation , *GENE expression , *DISEASE progression - Abstract
Abstract: Epigenetic inactivation of genes by DNA hypermethylation plays an important role in carcinogenesis. An in vitro model of human breast epithelial cell transformation was used to study epigenetic changes induced by estradiol during the neoplastic process. Different stages of tumor initiation and progression are represented in this model being MCF-10F the normal stage; trMCF cells, the transformed stage; bsMCF cells, the invasive stage and, caMCF cells, the tumor stage. Global methylation studies by restriction landmark genomic scanning (RLGS) showed an increased DNA methylation during the in the invasive and tumor stages. Expression studies showed that NRG1 (neuregulin 1), CSS3 (chondroitin sulfate synthase 3) and SNIP (SNAP-25-interacting protein) were downregulated in the invasive and tumor cells. The transformed cells showed low expression of STXBP6 (amysin) compared to the parental cells MCF-10F. The treatment of these cells with the demethylating agent 5-aza-dC alone or in combination with the histone deacetylase inhibitor trichostatin increased the expression of NRG1, STXBP6, CSS3 and SNIP confirming that DNA methylation plays an important role in the regulation of the expression of these genes. The NRG1 exon 1 has a region located between −136 and +79 (considering +1, the translational initiation site) rich in CpG sites that was analyzed by methylation specific PCR (MSP). NRG1 exon 1 showed progressive changes in the methylation pattern associated with the progression of the neoplastic process in this model; NRG1 exon 1 was unmethylated in MCF-10F and trMCF cells, becoming hypermethylated in the invasive (bsMCF) and tumor (caMCF) stages. Studies of human breast tissue samples showed that NRG1 exon 1 was partially methylated in 14 out of 17 (82.4%) invasive carcinomas although it was unmethylated in normal tissues (8 out of 10 normal breast tissue samples). Furthermore, NRG1 exon 1 was partially methylated in 9 out of 14 (64.3%) morphologically normal tissue samples adjacent to invasive carcinomas. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
18. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
- Author
-
Yan, Pearlly, Frankhouser, David, Murphy, Mark, Tam, Hok-Hei, Rodriguez, Benjamin, Curfman, John, Trimarchi, Michael, Geyer, Susan, Wu, Yue-Zhong, Whitman, Susan R., Metzeler, Klaus, Walker, Alison, Klisovic, Rebecca, Jacob, Samson, Grever, Michael R., Byrd, John C., Bloomfield, Clara D., Garzon, Ramiro, Blum, William, and Caligiuri, Michael A.
- Subjects
- *
ACUTE myeloid leukemia , *METHYLATION , *BONE marrow , *DECITABINE , *CPG nucleotides , *CANCER , *DEOXYRIBOSE - Abstract
The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, lowdose (20 mg/m2 per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellent toxicity profile. To assess the genomewide activity of decitabine, we profiled pretreatment and post treatment (day 25/course 1) methylomes of marrow samples from patients (n = 16) participating in the trial using deepsequencing analysis of methylated DNA captured by methylbinding protein (MBD2). Decitabine significantly reduced global methylation compared with pretreatment baseline (P=.001). Percent marrow blasts did not correlate with global methylation levels, suggesting that hypomethylation was related to the activity of decitabine rather than to a mere decrease in leukemia burden. Hypomethylation occurred predominantly in CpG islands and CpG islandassociated regions (P ranged from .03 to .04) A significant concentration (P<.001) of the hypomehtylated CpG Islands was found In chromosome subtelomeric regions, suggesting a differential activity of decitabine in distinct chromosome regions. Hypermethylation occurred much less frequently than hypomethylation and was associated with low CpG content regions. Decitabinerelated methylation changes were concordant with those previously reported in distinct genes. In summary, our study supports the feasibility of methylome analyses as a pharmacodynamic endpoint for hypomethylating therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
19. A NotI–EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies
- Author
-
Yu, Li, Liu, Chunhui, Bennett, Kristi, Wu, Yue-Zhong, Dai, Zunyan, Vandeusen, Jeff, Opavsky, Rene, Raval, Aparna, Trikha, Prashant, Rodriguez, Ben, Becknell, Brian, Mao, Charlene, Lee, Stephen, Davuluri, Ramana V., Leone, Gustavo, Van den Veyver, Ignatia B., Caligiuri, Michael A., and Plass, Christoph
- Subjects
- *
METHYLATION , *TUMORS , *GENETIC engineering , *LYMPHOPROLIFERATIVE disorders - Abstract
Aberrant promoter methylation and associated chromatin changes are primarily studied in human malignancies. Thus far, mouse models for human cancer have been rarely utilized to study the role of DNA methylation in tumor onset and progression. It would be advantageous to use mouse tumor models to a greater extent to study the role and mechanism of DNA methylation in cancer because mouse models allow manipulation of the genome, study of samples/populations with a homogeneous genetic background, the possibility of modulating gene expression in vivo, the statistical power of using large numbers of tumor samples, access to various tumor stages, and the possibility of preclinical trials. Therefore, it is likely that the mouse will emerge as an increasingly utilized model to study DNA methylation in cancer. To foster the use of mouse models, we developed an arrayed mouse NotI–EcoRV genomic library, with clones from three commonly used mouse strains (129SvIMJ, FVB/NJ, and C57BL/6J). A total of 23,040 clones representing an estimated three- to fourfold coverage of the mouse genome were arrayed in 60 × 384-well plates. We developed restriction landmark genomic scanning (RLGS) mixing gels with 32 plates to enable the cloning of methylated sequences from RLGS profiles run with NotI–EcoRV–HinfI. RLGS was used to study aberrant methylation in two mouse models that overexpressed IL-15 or c-Myc and developed either T/NK-cell leukemia or T-cell lymphomas, respectively. Careful analysis of 198 sequences showed that 188 (94.9%) identified CpG-island sequences, 132 sequences (66.7%) had homology to the 5′ regions of known genes or mRNAs, and all 132 NotI–EcoRV clones were located at the same CpG islands with the predicted promoter sequences. We have also developed a modified pGL3-based luciferase vector that now contains the NotI, AscI, and EcoRV restriction sites and allows the rapid cloning of NotI–EcoRV library fragments in both orientations. Luciferase assays using NotI–EcoRV clones confirmed that the library is enriched for promoter sequences. Thus, this library will support future genetic and epigenetic studies in mouse models. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.